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Introduction
The prevalence of juvenile idiopathic arthritis (JIA) in
Ukrainian children’s population is 4.1 per 10 000 and the
total number of children with JIA is about 3000. JIA
couldn’t be considered as a benign disease, because very
often it results in a sustainable disability. Previously was
shown, that early diagnostic and treatment lead to better
results. TNF is a key proinflammatory cytokine in the
pathogenesis of oligoarthicular and polyarthicular forms
of JIA. TNF-inhibition can prevent irreversible structural
joint damage. In children with methotrexate failure the
after treatment with biologic agents reduces the number
of disease flares by 54%. Adalimumab, the anti-TNF-
alpha recombinant human monoclonal antibody, recently
had been approved in Ukraine for the treatment of poly-
arthicular juvenil arthritis in children and was included
to the state JIA treatment funding programme.
Objectives
The objective of the study is to summarize the short-
term experience of adalimumab treatment in patients
with different types of JIA.
Methods
During the 2013 in the National Children’s Hospital
“Ohmatdyt” 79 patients with JIA were treated, aged 5 to
16 years (median -12,5 years), 31 boys and 48 girls. Among
girls dominated persistent oligoarthritis and systemic
arthritis (50% and 29%, respectively). Boys mostly had poly-
arthritis, RF-negative and persistent oligoarthritis (48.2%
and 22.8%, respectively). 7 children (8.8%) were HLA B27
positive: 6 boys and 1 girl. 7 of all patients were treated
with adalimumab and DMARDs. All children on adalimu-
mab were boys with age from 9 to 16 years (adalimumab
in Ukraine is approved from 4 y.o.). 6 children had
polyarthicular course of JIA, 1 – systemic arthritis. Among
them 1 was RF-positive, 1 HLA-B27 positive and 1 had
uveitis. RF, HLA-B27 positive patients and patient with sys-
temic arthritis had recurrent courses of disease.
Children with body weight less than 30 kg were given
20mg of adalimumab eow, and if body weight was 30 kg
and more – 40mg eow. All patients previously failed to
answer to NSAIDs, methotrexate, sulfasalazine or cyclos-
porine A. The duration from onset of the disease varied
from 2 to 10 years. Before the initiation of anti-TNF ther-
apy the TB-infection in all children was excluded by tuber-
culin and diaskin tests screening.
Results
In all patients adalimumab has been prescribed in combi-
nation with DMARDs as a second line therapy (n=1, time
from onset 2 y.) and as a third line therapy (n=6, time
from onset 3-10 ys.). On week 16 all patients met ACR
Pedi 30 response criteria, mainly due to reduction of
acute joint count and physician global assessment of dis-
ease activity. In 4 patients the corticosteroid daily dose
and in 1 patient the cyclosporine A dosage were reduced.
This led to the decrease of hypercorticism’ manifestations
and in 2 patients with nanism the tendency to the
height’s normalization was outlined. In a child with
poliarthritis associated uveitis the stabilization of eye
pressure and red blood picture were observed. Two boys
still had an active arthritis; one of them was RF+, that is a
predictor of poor prognosis. Adalimumab was well toler-
ated, no skin reactions and infections noticed. As of
today the follow up period is 5-8 months and our results
are concordant with the data of published randomized
clinical trials.
Conclusion
In patients with JIA adalimumab demonstrated an accep-
table safety profile, good tolerance and effectiveness,Pediatrics, P.L.Shupyk National Medical Academy for Postgraduate Education,
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